Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Piperacillin + Tazobactam, ATC J01CR05 für die Zeit 01.06.2026 - 31.05.2028 (zzgl. V.-Option 1x12 Monate)

Section 130a, paragraph 8, of the SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned substance Piperacillin + Tazobactam, ATC J01CR05, the DAK-Gesundheit intends to conclude discount contracts with as many interested pharmaceutical companies as possible until new drug discount contracts come into force. A discount contract under the approval model for the aforementioned substance will come into force for the first time on 01.06.2026 and will end on 31.05.2028 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive contract, regardless.